학술논문
MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers
Document Type
Report
Author
Source
Pulmonary Pharmacology & Therapeutics. June, 2008, Vol. 21 Issue 3, p573, 5 p.
Subject
Language
English
ISSN
1094-5539
Abstract
To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.pupt.2008.01.009 Byline: J.D. Boot (a), S.L. De Haas (a), J.M.A. Van Gerven (a), M. De Smet (b), T. Leathem (b), J. Wagner (c), A. Denker (c), D. Miller (c), M.B.A. Van Doorn (a), R.C. Schoemaker (a), A.F. Cohen (a), Z. Diamant (a) Keywords: Theophylline; MK-0873; Interaction; Pharmacokinetics Abstract: MK-0873 is a novel selective phosphodiesterase-4 inhibitor, which has been in development for the treatment of chronic obstructive pulmonary disease (COPD). In this indication, theophylline is still an important treatment, despite its relatively small therapeutic window. In view of this, it is important to investigate whether MK-0873 could affect the pharmacokinetics, safety and tolerability of theophylline, when both drugs are given concomitantly. Author Affiliation: (a) Centre for Human Drug Research , Zernikedreef 10, 2333 CL Leiden, The Netherlands (b) Merck Clinical Pharmacology, Brussels, Belgium (c) Merck Research Laboratories, Rahway, USA Article History: Received 8 November 2007; Revised 9 January 2008; Accepted 28 January 2008